{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:01:19Z","timestamp":1791493279055,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-0094"],"award-info":[{"award-number":["YTP-SYSUCC-0094"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-0028"],"award-info":[{"award-number":["CIRP-SYSUCC-0028"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SL2022A04J01033"],"award-info":[{"award-number":["SL2022A04J01033"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241232"],"award-info":[{"award-number":["82241232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473346"],"award-info":[{"award-number":["82473346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ccell.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:42:17Z","timestamp":1776955337000},"page":"983-994.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial"],"prefix":"10.1016","volume":"44","author":[{"given":"Yuxiang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangzhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qitao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-3888","authenticated-orcid":false,"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.03.018_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ccell.2026.03.018_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.03.018_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083802","article-title":"Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications","volume":"26","author":"Theik","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ccell.2026.03.018_bib4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 re-arrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.thorsurg.2020.01.007","article-title":"ROS1-rearranged Non-small Cell Lung Cancer","volume":"30","author":"Giustini","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.ccell.2026.03.018_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.20517\/cdr.2022.105","article-title":"Importance of ROS1 gene fusions in non-small cell lung cancer","volume":"6","author":"Muminovic","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ccell.2026.03.018_bib7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent Advances in Targeting ROS1 in Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70017","article-title":"Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer","volume":"14","author":"Desilets","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ccell.2026.03.018_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35784","article-title":"Targeting ROS1 re-arrangements in non-small cell lung cancer: Current insights and future directions","volume":"131","author":"Desilets","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2026.03.018_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/clinchem\/hvae008","article-title":"Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Non-small Cell Lung Cancer","volume":"70","author":"Zhao","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ccell.2026.03.018_bib11","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.03.018_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib13","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ccell.2026.03.018_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.03.018_bib15","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib17","doi-asserted-by":"crossref","first-page":"E5381","DOI":"10.1073\/pnas.1515281112","article-title":"Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors","volume":"112","author":"Davare","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2026.03.018_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2025.5097","article-title":"Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"12","author":"Ahn","year":"2026","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/1535-7163.MCT-25-0025","article-title":"Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations","volume":"24","author":"Tangpeerachaikul","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.03.018_bib20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","article-title":"NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.03.018_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib22","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-20-1630","article-title":"U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK Inhibitor, in Patients with Advanced Solid Tumors","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.03.018_bib23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.03.018_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-023-01454-z","article-title":"Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I\/II Trial","volume":"8","author":"Lu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ccell.2026.03.018_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(24)00171-1","article-title":"Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study","volume":"12","author":"Yang","year":"2024","journal-title":"Lancet Respir. Med."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:41:25Z","timestamp":1783057285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1535610826001728"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.03.018","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}